By transcriptomic analysis of NIBIT-M4 trial tumor lesions [63] we also found that several B cell-, TLS-, TEX- and IFNG-related gene signatures were selectively upregulated in on-treatment lesions from responding patients compared to non-responding ones. The gene discussed is TEX46; the disease is neoplasm.